NMTR Stock Price, 9 Meters Biopharma Inc Quote, Chart

Market Summary

USD0.020.00

Delayed

0.00%

NMTR Stock Price

View Fullscreen

NMTR RSI Chart

NMTR Valuation

Market Cap

289.2K

Price/Earnings (Trailing)

-0.01

Price/Sales (Trailing)

0.77

EV/EBITDA

0.16

Price/Free Cashflow

-0.01

NMTR Price/Sales (Trailing)

NMTR Profitability

Free Cashflow Yield

-12.9K%

NMTR Fundamentals

NMTR Revenue

NMTR Earnings

Breaking Down NMTR Revenue

Last 7 days

100%

Last 90 days

-97.0%

Trailing 12 Months

-99.6%

How does NMTR drawdown profile look like?

NMTR Financial Health

NMTR Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	374.6K	0	0	0
2022	30.4K	89.2K	219.5K	0
2021	19.9K	20.8K	21.8K	22.7K
2020	169.8K	151.9K	82.5K	19.0K
2019	173.6K	183.4K	193.2K	0
2018	0	0	1.0M	163.8K
2017	4.5M	3.0M	2.3M	1.9M
2016	7.4M	7.8M	4.4M	4.1M
2015	0	10.3M	9.3M	8.3M
2014	0	0	0	11.3M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of 9 Meters Biopharma Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 21, 2023	sensenig bethany	sold	-11,011	1.21	-9,100	chief financial officer
Mar 29, 2023	johnson lorin k	acquired	-	-	7,885	-
Mar 29, 2023	rice yehuda michael	acquired	-	-	7,885	-
Mar 29, 2023	ventimiglia samantha	acquired	-	-	7,885	-
Mar 29, 2023	sirgo mark a	acquired	-	-	7,885	-
Mar 29, 2023	constantino michael t.	acquired	-	-	7,885	-
Mar 27, 2023	sensenig bethany	acquired	-	-	50,177	chief financial officer
Mar 27, 2023	temperato john	acquired	-	-	68,815	chief executive officer
Jul 06, 2022	temperato john	bought	28,462	0.2277	125,000	chief executive officer
Jul 01, 2022	sirgo mark a	bought	42,962	0.2455	175,000	-

Which funds bought or sold NMTR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Feb 13, 2024	Strategic Investment Solutions, Inc. /IL	reduced	-98.41	-2,284	-	-%
Feb 14, 2023	Axiom Investment Management LLC	sold off	-100	-	-	-%
Nov 14, 2022	REGENTATLANTIC CAPITAL LLC	sold off	-100	-11,000	-	-%
Nov 10, 2022	Ashfield Capital Partners, LLC	unchanged	-	-2,000	7,000	-%
Oct 26, 2022	WIPFLI FINANCIAL ADVISORS LLC,	new	-	1,000	1,000	-%
Aug 15, 2022	Frontier Wealth Management LLC	unchanged	-	-7,000	8,000	-%
May 16, 2022	Amalgamated Financial Corp.	new	-	22,000	22,000	-%

Are Funds Buying or Selling NMTR?

Are funds buying NMTR calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NMTR

No. of Funds

Unveiling 9 Meters Biopharma Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 07, 2024	adage capital partners gp, l.l.c.	0%	0	SC 13G/A
Feb 09, 2023	adage capital partners gp, l.l.c.	5.02%	650,000	SC 13G/A
Jul 08, 2022	blackrock inc.	1.3%	3,370,798	SC 13G
Jul 01, 2022	orbimed israel biofund gp limited partnership	4.6%	12,356,873	SC 13D/A
Feb 04, 2022	blackrock inc.	5.5%	14,164,801	SC 13G
Jun 28, 2021	orbimed israel biofund gp limited partnership	6.0%	15,384,418	SC 13D/A
Apr 07, 2021	orbimed israel biofund gp limited partnership	13.2%	32,503,255	SC 13D/A
Mar 25, 2021	orbimed israel biofund gp limited partnership	14.6%	32,503,255	SC 13D/A
Dec 28, 2020	adage capital partners gp, l.l.c.	6.41%	1.3e+07	SC 13G
Dec 16, 2020	orbimed israel biofund gp limited partnership	16.0%	32,503,255	SC 13D/A

9 Meters Biopharma Inc News

Latest updates

9 Meters Biopharma Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q1	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2017Q4	2017Q3	2017Q2	2017Q1
Revenue	25.2%	164,787	131,655	65,319	12,814	9,718	1,397	6,505	5,087	4,191	3,295	8,550	12,815	57,848	72,641	26,456	36,272	321,386	606,500	138,000	187,000	951,000
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	91,500	-70,000	-39,000	-47,000
Operating Expenses	46.7%	12,787,491	8,715,985	11,195,421	11,364,249	9,564,698	13,539,658	8,258,461	5,399,102	4,775,449	6,304,199	44,838,479	4,959,631	6,507,928	6,123,055	4,312,810	3,739,033	-219,653	2,221,648	2,340,807	2,690,839	-
S&GA Expenses	23.6%	2,988,200	2,417,484	3,648,944	2,995,771	2,516,443	2,386,461	2,551,171	2,208,800	1,299,935	1,890,492	5,659,721	1,669,807	2,564,508	3,049,711	3,114,495	1,995,536	1,565,992	1,046,524	1,973,256	1,561,106	-
R&D Expenses	-	-	-	-	-	-	-	-	-	-	-	-	2,598,985	3,943,420	3,073,344	1,198,315	1,743,497	-1,785,645	1,175,124	367,551	1,129,733	1,335,503
EBITDA Margin	40.4%	-114	-191	-529	-1,654	-2,255	-1,952	-1,044	-2,010	-696	-741	-419	-142	-	-	-	-	-	-	-	-	-
Interest Expenses	-11.2%	752,820	847,341	-	304	-	1,970	1,154	44,064	335,498	2,118,433	1,019,307	572,985	472,052	431,626	427,245	558,292	1,038,014	154,656	110,508	99,483	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-48.3%	-13,868,457	-9,354,671	-11,130,102	-11,351,739	-9,554,980	-13,540,231	-8,253,110	-5,431,079	-4,962,615	-8,333,337	-44,597,536	-3,603,001	-9,221,232	-4,488,240	-4,434,765	-4,211,053	-775,930	-2,376,304	-2,451,315	-2,790,322	-
EBT Margin	37.0%	-123	-196	-529	-1,654	-2,258	-1,976	-1,151	-2,128	-745	-793	-436	-154	-	-	-	-	-	-	-	-	-
Net Income	-48.3%	-13,868,457	-9,354,671	-11,130,102	-11,351,739	-9,554,980	-13,540,231	-8,253,110	-5,431,079	-4,962,615	-8,333,337	-44,597,536	-3,603,001	-9,221,232	-4,488,240	-4,434,765	-4,211,053	-775,930	-2,376,304	-2,451,315	-2,790,322	-
Net Income Margin	37.0%	-123	-196	-529	-1,654	-2,258	-1,976	-1,151	-2,128	-745	-793	-436	-154	-	-	-	-	-	-	-	-	-
Free Cashflow	2.2%	-9,749,676	-9,969,952	-7,786,324	-9,751,173	-7,973,295	-8,176,743	-7,110,701	-6,230,012	-6,418,495	-4,161,335	-6,200,114	-2,632,385	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1
Assets	-71.9%	9.00	33.00	42.00	32.00	39.00	50.00	57.00	66.00	40.00	39.00	14.00	15.00	3.00	5.00	10.00	15.00	13.00	6.00	9.00	11.00	13.00
Current Assets	-72.1%	9.00	33.00	18.00	31.00	39.00	50.00	56.00	66.00	40.00	39.00	14.00	15.00	3.00	5.00	10.00	15.00	12.00	6.00	9.00	11.00	13.00
Cash Equivalents	-45.1%	7.00	13.00	16.00	29.00	37.00	47.00	54.00	64.00	38.00	38.00	12.00	13.00	3.00	5.00	9.00	13.00	11.00	6.00	8.00	11.00	13.00
Net PPE	-12.8%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-49.2%	16.00	31.00	29.00	9.00	8.00	9.00	7.00	7.00	6.00	7.00	10.00	12.00	13.00	15.00	-	10.00	11.00	10.00	-	-	-
Current Liabilities	-49.3%	16.00	31.00	13.00	9.00	8.00	8.00	7.00	7.00	6.00	7.00	10.00	12.00	16.00	15.00	13.00	10.00	11.00	10.00	8.00	7.00	5.00
Shareholder's Equity	-100.0%	-	2.00	13.00	22.00	31.00	42.00	49.00	59.00	34.00	32.00	4.00	3.00	-	-	-	5.00	2.00	-	0.00	3.00	8.00
Retained Earnings	-6.5%	-226	-212	-200	-191	-180	-168	-159	-145	-137	-132	-127	-118	-74.17	-70.56	-61.66	-52.44	-47.95	-43.52	-39.30	-38.53	-34.31
Additional Paid-In Capital	2.4%	220	215	214	213	211	210	209	205	172	164	131	122	62.00	61.00	58.00	57.00	50.00	40.00	40.00	42.00	42.00
Shares Outstanding	10.0%	14.00	13.00	13.00	13.00	13.00	13.00	12.00	12.00	11.00	10.00	7.00	3.00	2.00	2.00	-	-	-	-	-	-	-
Float	-	-	-	-	67.00	-	-	-	275	-	-	-	62.00	-	-	-	40.00	-	-	-	313	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1
Cashflow From Operations	-0.1%	-9,749	-9,738	-9,969	-7,786	-9,748	-7,970	-8,173	-7,108	-6,225	-6,418	-4,161	-6,197	-2,632	-3,223	-3,988	-6,517	-4,237	-2,408	-3,479	-2,313	-6,967
Share Based Compensation	-0.9%	737	744	730	1,774	690	529	525	937	422	224	202	4,021	276	593	900	852	526	-54.00	-3,131	-184	7,174
Cashflow From Investing	-	-	-	-	-	-2.84	-2.63	-2,421	-1.88	-5.01	-	-	-3,187	-	-2.46	-	-9.47	-	-75.00	-	-	61.00
Cashflow From Financing	-Infinity%	-12,285	-	19,912	-	-	1,358	180	32,638	6,875	31,834	3,124	20,190	707	-1,044	-485	8,370	10,004	101	928	-	19,528

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

NMTR Income Statement

2023-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

3 Months Ended

Mar. 31, 2023

USD ($)

$ / shares

shares

Mar. 31, 2022

USD ($)

$ / shares

shares

Operating expenses:

Research and development

$ 9,799,291

$ 8,368,478

General and administrative

2,988,200

2,995,771

Total operating expenses

12,787,491

11,364,249

Loss from operations

(12,787,491)

(11,364,249)

Other income (expense):

Interest income, net

164,787

12,814

Interest expense

(752,820)

(304)

Loss on extinguishment of convertible note payable

(414,291)

0

Change in fair value of derivative liability

(78,642)

0

Total other income (expense), net

(1,080,966)

12,510

Loss before income taxes

(13,868,457)

(11,351,739)

Income tax benefit

0

Net loss

$ (13,868,457)

$ (11,351,739)

Net loss per common share, basic (in dollars per share) | $ / shares

^[1]

$ (1.02)

$ (0.88)

Net loss per common share, diluted (in dollars per share) | $ / shares

^[1]

$ (1.02)

$ (0.88)

Weighted-average common shares, basic (in shares) | shares

^[1]

13,591,912

12,911,776

Weighted-average common shares, diluted (in shares) | shares

^[1]

13,591,912

12,911,776

[1]	Amounts have been retroactively restated to reflect the 1-for-20 reverse stock split effected on October 17, 2022 (see Note 1)

NMTR Balance Sheet

2023-03-31

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 6,938,991	$ 12,646,282
Prepaid expenses and other current assets	1,573,725	3,358,917
Restricted cash	684,587	17,012,650
Total current assets	9,197,303	33,017,849
Property and equipment, net	9,084	10,413
Right-of-use asset	97,670	112,302
Other assets	8,980	7,280
Total assets	9,313,037	33,147,844
Current liabilities:
Accounts payable	4,231,034	5,053,073
Accrued expenses	5,757,675	4,379,773
Convertible note payable, net	5,071,143	19,616,313
Derivative liability	454,000	1,585,000
Lease liability, current portion	63,617	61,746
Total current liabilities	15,577,469	30,695,905
Lease liability, net of current portion	34,773	51,396
Total liabilities	15,612,242	30,747,301
Commitments and contingencies (Note 8)
Stockholders’ equity (deficit):
Preferred stock $0.0001 par value per share, 10,000,000 shares authorized; 0 shares issued and outstanding as of March 31, 2023 (unaudited) and December 31, 2022	0	0
Common stock $0.0001 par value per share, 550,000,000 shares authorized as of March 31, 2023 (unaudited) and December 31, 2022; 14,336,356 and 13,036,356 shares issued and outstanding as of March 31, 2023 (unaudited) and December 31, 2022, respectively	1,434	1,304
Additional paid-in capital	220,174,900	215,006,321
Accumulated deficit	(226,475,539)	(212,607,082)
Total stockholders’ equity (deficit)	(6,299,205)	2,400,543
Total liabilities and stockholders’ equity (deficit)	$ 9,313,037	$ 33,147,844

About 9 Meters Biopharma Inc

0

WEBSITE	9meters.com

9 Meters Biopharma Inc Frequently Asked Questions

What is the ticker symbol for 9 Meters Biopharma Inc? What does NMTR stand for in stocks?

NMTR is the stock ticker symbol of 9 Meters Biopharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of 9 Meters Biopharma Inc (NMTR)?

As of Tue Sep 26 2023, market cap of 9 Meters Biopharma Inc is 289.19 Thousand. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NMTR stock?

You can check NMTR's fair value in chart for subscribers.

What is the fair value of NMTR stock?

You can check NMTR's fair value in chart for subscribers. The fair value of 9 Meters Biopharma Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of 9 Meters Biopharma Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NMTR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is 9 Meters Biopharma Inc a good stock to buy?

The fair value guage provides a quick view whether NMTR is over valued or under valued. Whether 9 Meters Biopharma Inc is cheap or expensive depends on the assumptions which impact 9 Meters Biopharma Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NMTR.

What is 9 Meters Biopharma Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Sep 26 2023, NMTR's PE ratio (Price to Earnings) is -0.01 and Price to Sales (PS) ratio is 0.77. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NMTR PE ratio will change depending on the future growth rate expectations of investors.